Combination of imatinib and established antileukemic treatment modalities for otherwise refractory BCR-ABL positive lymphoblastic leukemia.
Fruehauf
Stefan
S
Department ofInternal Medicine V, University of Heidelberg, Germany. stefan_fruehauf@med.uni-heidelberg.de
Topaly
Julian
J
Buss
Eike C
EC
Schad
Moritz
M
Goerner
Martin
M
Zeller
W Jens
WJ
Ho
Anthony D
AD
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001549:Benzamides; D003131:Combined Modality Therapy; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D000068877:Imatinib Mesylate; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods; D010879:Piperazines / Q000008:administration & dosage*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D011743:Pyrimidines / Q000008:administration & dosage*; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction / Q000379:methods; D016879:Salvage Therapy; D019172:Transplantation Conditioning / Q000379:methods
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl